Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2306, a Proposed Biosimilar of Cosenty

GUANGZHOU, China--(BUSINESS WIRE)--#ActiveAnkylosingSpondylitis--Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase III clinical study for BAT2306, a proposed biosimilar of Cosentyx® (secukinumab). The clinical study is a randomized, dou...

Related Keywords

China ,Guangzhou ,Guangdong ,Wechat Bio Thera ,Abbvie Biotechnology Ltd ,Chugai Seiyaku Kabushiki Kaisha Corporation ,Twitter ,Genentech Inc ,Johnson Corporation ,Bio Thera Solutions Ltd ,Bio Thera Solutions ,Activeankylosingspondylitis Bio Thera Solutions Ltd ,Activeankylosingspondylitis Bio Thera Solutions ,Thera Solutions ,